My Best Pick 2021

Gautam Trivedi spots an opportunity in the making of an Indian MNC

SeQuent Scientific has recorded stellar financial performance in an industry with wide-moat, and now it has the guidance of a global PE firm 

Faisal Magray









Over the past two to three years, we have seen global private equity (PE) companies buying out listed, Indian midcap companies. There was, for example, Advent buying into DFM Foods, Blackstone buying Essel Propack and KKR buying out the founders of JB Chemicals (a Nepean Capital investee company).

As a result, most of these companies have seen a re-rating since there is a perception that companies having PE funds as owners/management are as good as ones managed by MNCs, in terms of governance, because of which their stocks trade at a premium compared to their local peers. 

One such company is SeQuent Scientific, a Nepean Capital portfolio company. It was carved out from Bengaluru-based Strides Arcolabs and, within just eight years of its founding, it has emerged as India’s largest animal-health company. With annual revenue of over $200 million, SeQuent is among the top 20 animal health


You don’t want to be left behind. Do you?

Our work is exclusively for discerning readers. To read our edgy stories and access our archives, you’ve to subscribe